title: Does improved insulin sensitivity by irbesartan at the highest tolerated dose provide a benefit in non-diabetic patients with systolic heart failure already receiving standardized treatment?
authors: State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardio-vascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, 167 North Lishi Road, Xicheng District, Beijing, 100037, People's Republic of China.
authors: Dan
authors: D
authors: Yang
authors: Zhihong
authors: Z
authors: Liu
mesh_terms: D057911:Angiotensin Receptor Antagonists / Q000627:therapeutic use*; D001713:Biphenyl Compounds / Q000627:therapeutic use*; D005260:Female; D054143:Heart Failure, Systolic / Q000188:drug therapy* / Q000503:physiopathology*; D006801:Humans; D007333:Insulin Resistance / Q000502:physiology*; D008297:Male; D013777:Tetrazoles / Q000627:therapeutic use*
chemical_list: D057911:Angiotensin Receptor Antagonists; D001713:Biphenyl Compounds; D013777:Tetrazoles
keywords: Asymmetric dimethylarginine; Chronic heart failure; Insulin sensitivity; Irbesartan; Systolic blood pressure; Tumor necrosis factor-alpha